接受免疫检查点抑制剂治疗的肺癌患者中活动性肺结核的发病率。
Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
作者信息
Fujita Kohei, Yamamoto Yuki, Kanai Osamu, Okamura Misato, Hashimoto Masayuki, Nakatani Koichi, Sawai Satoru, Mio Tadashi
机构信息
Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Department of Drug Discovery for Lung Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
出版信息
Open Forum Infect Dis. 2020 Apr 9;7(5):ofaa126. doi: 10.1093/ofid/ofaa126. eCollection 2020 May.
Abstract
Although it ameliorates lung cancer, immunotherapy with immune checkpoint inhibitors (ICIs) presents complications of infectious diseases, including tuberculosis. Incidence of tuberculosis during immunotherapy remains unclear. We found that 1.7% of patients developed active tuberculosis during immunotherapy at our institution. In patients with a positive interferon-gamma release assay status before ICI therapy, physicians should pay close attention to developing tuberculosis.
摘要
尽管免疫检查点抑制剂（ICI）免疫疗法可改善肺癌，但会引发包括结核病在内的传染病并发症。免疫疗法期间结核病的发病率仍不明确。我们发现，在我们机构接受免疫疗法的患者中，有1.7%发生了活动性结核病。对于ICI治疗前干扰素-γ释放试验结果呈阳性的患者，医生应密切关注结核病的发生。
相似文献
1
Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.接受免疫检查点抑制剂治疗的肺癌患者中活动性肺结核的发病率。
Open Forum Infect Dis. 2020 Apr 9;7(5):ofaa126. doi: 10.1093/ofid/ofaa126. eCollection 2020 May.
2
Serial interferon-gamma release assay in lung cancer patients receiving immune checkpoint inhibitors: a prospective cohort study.肺癌患者接受免疫检查点抑制剂治疗时的序贯干扰素-γ释放试验：一项前瞻性队列研究。
Cancer Immunol Immunother. 2022 Nov;71(11):2757-2764. doi: 10.1007/s00262-022-03198-1. Epub 2022 Apr 16.
3
Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy.免疫检查点抑制剂治疗的肺癌患者中传染病的新关注点。
Respir Med. 2019 Jan;146:66-70. doi: 10.1016/j.rmed.2018.11.021. Epub 2018 Dec 13.
4
Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors.癌症患者接受免疫检查点抑制剂治疗后发生结核病。
Respir Med. 2020 Jan;161:105853. doi: 10.1016/j.rmed.2019.105853. Epub 2019 Dec 14.
5
The Levels of Interferon-gamma Release as a Biomarker for Non-small-cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.干扰素-γ释放作为接受免疫检查点抑制剂治疗的非小细胞肺癌患者的生物标志物的水平。
Anticancer Res. 2019 Nov;39(11):6231-6240. doi: 10.21873/anticanres.13832.
6
Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).非小细胞肺癌（NSCLC）中的免疫检查点抑制剂（ICIs）。
J UOEH. 2018;40(2):173-189. doi: 10.7888/juoeh.40.173.
7
Development of Complex Lung Disease in Patients With Lung Cancer on Immune Checkpoint Inhibitors.接受免疫检查点抑制剂治疗的肺癌患者复杂肺部疾病的发生
Open Forum Infect Dis. 2020 Mar 7;7(3):ofaa067. doi: 10.1093/ofid/ofaa067. eCollection 2020 Mar.
8
Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities.免疫检查点抑制剂治疗非小细胞肺癌：获益与肺部毒性。
Chest. 2018 Dec;154(6):1416-1423. doi: 10.1016/j.chest.2018.08.1048. Epub 2018 Sep 4.
9
Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.晚期非小细胞肺癌患者接受免疫检查点抑制剂治疗时抗生素的预测影响：抗生素免疫检查点抑制剂在晚期 NSCLC 中的应用。
Cancer Chemother Pharmacol. 2020 Jan;85(1):121-131. doi: 10.1007/s00280-019-03993-1. Epub 2019 Nov 19.
10
Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.免疫检查点抑制剂治疗非小细胞肺癌患者的肺炎：发生率和危险因素。
J Thorac Oncol. 2018 Dec;13(12):1930-1939. doi: 10.1016/j.jtho.2018.08.2035. Epub 2018 Sep 26.
引用本文的文献
1
Where lung cancer and tuberculosis intersect: recent advances.肺癌与结核病的交叉领域：最新进展
Front Immunol. 2025 Apr 2;16:1561719. doi: 10.3389/fimmu.2025.1561719. eCollection 2025.
2
The blood biomarker combination IL-8/IL-33 and IL-18/IL-33 distinguish between active tuberculosis and latent infection.血液生物标志物组合白细胞介素-8/白细胞介素-33和白细胞介素-18/白细胞介素-33可区分活动性肺结核和潜伏感染。
Infection. 2025 Mar 17. doi: 10.1007/s15010-024-02454-z.
3
Simultaneous Anti-Tuberculosis and Anti-Tumor Treatment with Immune Checkpoint Inhibitors for Co-Existent Pulmonary Tuberculosis and Advanced Lung Cancer.免疫检查点抑制剂同步抗结核与抗肿瘤治疗并存的肺结核和晚期肺癌
Infect Drug Resist. 2025 Jan 6;18:107-112. doi: 10.2147/IDR.S497006. eCollection 2025.
4
The controversy of immune checkpoint inhibition and risk of mycobacterial infections: the need for further studies and continued discussions on this puzzling issue.免疫检查点抑制与分枝杆菌感染风险的争议：对这一棘手问题进行进一步研究并持续讨论的必要性。
J Thorac Dis. 2024 Aug 31;16(8):5487-5489. doi: 10.21037/jtd-24-1005. Epub 2024 Aug 28.
5
Safety of nivolumab monotherapy in five cancer types: pooled analysis of post-marketing surveillance in Japan.五种癌症类型中单药纳武利尤单抗治疗的安全性：日本上市后监测的汇总分析。
Int J Clin Oncol. 2024 Jul;29(7):932-943. doi: 10.1007/s10147-024-02515-1. Epub 2024 Jun 6.
6
Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Respiratory Disease; Interstitial Pneumonia, Chronic Obstructive Pulmonary Disease, and Tuberculosis.合并呼吸系统疾病的非小细胞肺癌的治疗策略；间质性肺炎、慢性阻塞性肺疾病和肺结核
Cancers (Basel). 2024 Apr 29;16(9):1734. doi: 10.3390/cancers16091734.
7
A narrative review of the controversy on the risk of mycobacterial infections with immune checkpoint inhibitor use: does Goldilocks have the answer?关于使用免疫检查点抑制剂引发分枝杆菌感染风险争议的叙述性综述：金发姑娘知道答案吗？
J Thorac Dis. 2024 Feb 29;16(2):1601-1624. doi: 10.21037/jtd-23-1395. Epub 2024 Feb 27.
8
Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy.接受免疫检查点抑制剂治疗的患者结核再激活风险增加。
Oncologist. 2024 Apr 4;29(4):e498-e506. doi: 10.1093/oncolo/oyad340.
9
10
Comparative immune responses to in people with latent infection or sterilizing protection.对潜伏感染或杀菌性保护人群的比较免疫反应。
iScience. 2023 Jul 20;26(8):107425. doi: 10.1016/j.isci.2023.107425. eCollection 2023 Aug 18.
本文引用的文献
1
Development of Complex Lung Disease in Patients With Lung Cancer on Immune Checkpoint Inhibitors.接受免疫检查点抑制剂治疗的肺癌患者复杂肺部疾病的发生
Open Forum Infect Dis. 2020 Mar 7;7(3):ofaa067. doi: 10.1093/ofid/ofaa067. eCollection 2020 Mar.
2
Immune checkpoint inhibitors and tuberculosis: an old disease in a new context.免疫检查点抑制剂与结核病：新形势下的老问题。
Lancet Oncol. 2020 Jan;21(1):e55-e65. doi: 10.1016/S1470-2045(19)30674-6.
3
Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy.免疫检查点抑制剂治疗的肺癌患者中传染病的新关注点。
Respir Med. 2019 Jan;146:66-70. doi: 10.1016/j.rmed.2018.11.021. Epub 2018 Dec 13.
4
Tuberculosis following PD-1 blockade for cancer immunotherapy.癌症免疫治疗后发生 PD-1 阻断相关的结核。
Sci Transl Med. 2019 Jan 16;11(475). doi: 10.1126/scitranslmed.aat2702.
5
Implications of Tuberculosis Reactivation after Immune Checkpoint Inhibition.免疫检查点抑制后结核病再激活的影响
Am J Respir Crit Care Med. 2018 Dec 1;198(11):1451-1453. doi: 10.1164/rccm.201807-1250LE.
6
Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents.一名接受纳武单抗治疗后再使用抗结核分枝杆菌药物的非小细胞肺癌患者出现的矛盾反应。
J Infect Chemother. 2019 Jan;25(1):54-58. doi: 10.1016/j.jiac.2018.06.016. Epub 2018 Jul 25.
7
Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment.肿瘤学中与使用免疫检查点抑制剂相关的感染并发症：抗PD-1治疗后结核病复发
Clin Microbiol Infect. 2018 Mar;24(3):216-218. doi: 10.1016/j.cmi.2017.12.003. Epub 2017 Dec 18.
8
Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis.实体瘤和血液恶性肿瘤患者的结核病风险：系统评价和荟萃分析。
Eur Respir J. 2017 Aug 24;50(2). doi: 10.1183/13993003.00157-2017. Print 2017 Aug.
9
Pericardial Tamponade Caused by a Hypersensitivity Response to Tuberculosis Reactivation after Anti-PD-1 Treatment in a Patient with Advanced Pulmonary Adenocarcinoma.一名晚期肺腺癌患者在接受抗PD-1治疗后，因结核再激活的超敏反应导致心包填塞。
J Thorac Oncol. 2017 Aug;12(8):e111-e114. doi: 10.1016/j.jtho.2017.03.012.
10
Risk of Active Tuberculosis in Patients with Cancer: A Systematic Review and Meta-Analysis.癌症患者活动性肺结核的风险：一项系统评价和荟萃分析。
Clin Infect Dis. 2017 Mar 1;64(5):635-644. doi: 10.1093/cid/ciw838. Epub 2016 Dec 16.
Zotero 插件